Cost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder
Lu T, Ryan D, Cadet T, Chawarski M, Coupet E, Edelman E, Hawk K, Huntley K, Jalali A, O'Connor P, Owens P, Martel S, Fiellin D, D'Onofrio G, Murphy S. Cost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder. Annals Of Emergency Medicine 2024 PMID: 39570250, DOI: 10.1016/j.annemergmed.2024.10.001.Peer-Reviewed Original ResearchHealth care sector perspectiveImplementation facilitatorsOpioid use disorder careIncremental cost-effectiveness ratioCost-effectiveness ratioHealth care sector costsEducational strategiesImplementation facilitation strategyCost-effectiveness acceptability curvesLikelihood of cost-effectivenessCost-effectiveOpioid use disorderQuality-adjusted life yearsUse disorderPatient engagementAcademic EDED visitsAcceptability curvesStandard educationEmergency departmentLife yearsFacilitation strategiesMeasures of effectivenessHealthBuprenorphineAn Urgent Need to Promote Equitable Buprenorphine Administration for Opioid Use Disorder in the Emergency Department.
Coupet E, Edelman E. An Urgent Need to Promote Equitable Buprenorphine Administration for Opioid Use Disorder in the Emergency Department. Journal Of Addiction Medicine 2024 PMID: 39514893, DOI: 10.1097/adm.0000000000001409.Peer-Reviewed Original ResearchBuprenorphine administrationOpioid use disorder treatmentOpioid use disorderUse disorderAddiction treatmentDisorder treatmentEmergency departmentED patientsCross-sectional study of ED patientsTreatment accessBuprenorphineStudy of ED patientsOpioidOpioid overdose deathsOpioid misuseOverdose deathsCross-sectional studyLatinosAddictionPromoting Race and Ethnic Diversity in a Hospital-Based Randomized Clinical Trial to Address Untreated Alcohol Use Disorder: Initial Lessons Learned.
Edelman E, Frankforter T, Rojas-Perez O, Ablondi K, Castro C, Corvino J, Garcia I, Gordon D, Jaramillo Y, Johnson N, Jordan A, Nich C, Paris M, Pagano D, Weimer M, Williams E, Kiluk B. Promoting Race and Ethnic Diversity in a Hospital-Based Randomized Clinical Trial to Address Untreated Alcohol Use Disorder: Initial Lessons Learned. Journal Of Addiction Medicine 2024 PMID: 39514895, DOI: 10.1097/adm.0000000000001400.Peer-Reviewed Original ResearchAlcohol use disorderBrief Negotiation InterviewUntreated alcohol use disorderUse disorderSocial determinants of healthCognitive behavioral therapyElectronic medical record dataDeterminants of healthEthnically diverse sampleMedical record dataMonths of recruitmentBehavioral therapyModifications-EnhancedReporting AdaptationsTreatment engagementEffectiveness of strategiesSocial determinantsInitiation of medicationRecruitment approachesDiverse samplePost-hospitalizationAlcohol useResearch staffParent trialRecord dataClinician and Practice Characteristics Associated With Support of Office-Based Methadone: Findings From a National Survey.
Sung M, Black A, Blevins D, Henry B, Cates-Wessel K, Dawes M, Hagle H, Joudrey P, Molfenter T, Levin F, Fiellin D, Edelman E. Clinician and Practice Characteristics Associated With Support of Office-Based Methadone: Findings From a National Survey. Journal Of Addiction Medicine 2024 PMID: 39475119, DOI: 10.1097/adm.0000000000001388.Peer-Reviewed Original ResearchOpioid use disorderCharacteristics associated with supportTreatment of opioid use disorderMultivariate logistic regression modelOffice-based settingSequential multivariable logistic regression modelsOpioid treatment programsLogistic regression modelsAcademic medical centerUse disorderInclusion criteriaMethadoneMedical CenterPatientsOffice-basedCOVID-19 surveyClinician supportPractice characteristicsLongitudinal treatmentImplementation barriersPolicy changesMOUDOutcome variablesImprove accessNational surveyThe Feasibility and Acceptability of a Clinical Pharmacist-delivered Intervention to Reduce Bothersome Health Symptoms from Polypharmacy and Alcohol Use and Communicate Risk among People with HIV: Pilot Study Protocol
Womack J, Leblanc M, Sager A, Zaets L, Maisto S, Garcia A, Aoun-Barakat L, Brown S, Edelman E, Fiellin D, Fisher J, Fraenkel L, Kidwai-Khan F, Marconi V, Martino S, Pulk R, Satre D, Virata M, Justice A, Hsieh E. The Feasibility and Acceptability of a Clinical Pharmacist-delivered Intervention to Reduce Bothersome Health Symptoms from Polypharmacy and Alcohol Use and Communicate Risk among People with HIV: Pilot Study Protocol. AIDS And Behavior 2024, 1-15. PMID: 39465468, DOI: 10.1007/s10461-024-04533-6.Peer-Reviewed Original ResearchUnhealthy alcohol useAlcohol usePharmacist-delivered interventionVeterans Aging Cohort StudyPilot study protocolStudy protocolElectronic health recordsSupport behavior changePre-test/post-test designAging Cohort StudySelf-administered surveyAlcohol use disorderAlcohol Research CenterBothersome symptomsPre-test/post-testCommunicating riskHealth recordsLong-term medicationHealth symptomsCounseling interventionCounseling sessionsSessions 2 weeksQualitative interviewsAlcohol consumptionUse disorderIntegrated stepped alcohol treatment with contingency management for unhealthy alcohol use among people with HIV: A randomized controlled trial.
Edelman E, Dziura J, Deng Y, DePhilippis D, Ferguson T, Brown S, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. Integrated stepped alcohol treatment with contingency management for unhealthy alcohol use among people with HIV: A randomized controlled trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024 PMID: 39321757, DOI: 10.1097/qai.0000000000003534.Peer-Reviewed Original ResearchUnhealthy alcohol useSelf-reported abstinenceAlcohol useLost to follow-upContingency managementAlcohol use disorderRandomized controlled trialsSubstance use treatmentAlcohol abstinenceFollow-upUse disorderControlled trialsPWHAlcohol treatmentAbstinenceUse treatmentEvidence of abstinenceHIVWeeksMean proportionTreatmentTrialsAlcoholDaysParticipantsPain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV
Miller E, McGinnis K, Edelman E, Feinberg T, Gordon K, Kerns R, Marshall B, Patterson J, McRae M. Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV. AIDS And Behavior 2024, 1-11. PMID: 39264485, DOI: 10.1007/s10461-024-04494-w.Peer-Reviewed Original ResearchMental health classesSubstance use disordersOpioid use disorderHIV statusBuprenorphine initiationVeterans Aging Cohort StudyInitiate buprenorphineMental health diagnosesAging Cohort StudyBuprenorphine treatmentMultiple pain conditionsAssociated with HIV statusInfluence treatment retentionUse disorderTreatment of opioid use disorderHigher comorbidity burdenAge of patientsClinical encountersMental healthHealth diagnosisBlack veteransHealth classesLatent class analysisCohort studyPrescription dataM145 Assessing Provider Readiness to Implement Pre-Exposure Prophylaxis for HIV Prevention and Medications for Opioid Use Disorder Among People who Inject Drugs
Pickering E, Sung M, Bailey G, Buchelli M, Davidson D, Jenkins M, John B, Kolakowski J, Maier L, Porter E, Perez O, Rash C, Edelman E, Viera A. M145 Assessing Provider Readiness to Implement Pre-Exposure Prophylaxis for HIV Prevention and Medications for Opioid Use Disorder Among People who Inject Drugs. Drug And Alcohol Dependence 2024, 260: 110425. DOI: 10.1016/j.drugalcdep.2023.110425.Peer-Reviewed Original ResearchDiscordance Between Insurance Coverage of Antiviral Medications and Nicotine Replacement Therapy Among Individuals With Human Immunodeficiency Virus Who Smoke
Bernstein S, Yager J, Sigel K, Porter E, Do T, Payne E, Bold K, Ledgerwood D, Edelman E. Discordance Between Insurance Coverage of Antiviral Medications and Nicotine Replacement Therapy Among Individuals With Human Immunodeficiency Virus Who Smoke. Journal Of Addiction Medicine 2024, 18: 404-407. PMID: 38606851, PMCID: PMC11290992, DOI: 10.1097/adm.0000000000001302.Peer-Reviewed Original ResearchNicotine replacement therapyHuman immunodeficiency virusTobacco use disorderAntiretroviral therapyReplacement therapyTobacco useImmunodeficiency virusCoverage of antiretroviral therapyInsurance coverageSecondary analysis of dataUse disorderManaged care planOut-of-pocketMandated insurance coverageCare planningEfficacy of antiviralsRandomized clinical trialsPharmacy benefit managersInsurance barriersMedication prescriptionsSecondary analysisTracking formParticipation AssessmentAntiviral medicationsPWH